Protagonist Therapeutics Inc. Common Stock (PTGX)
Stock · NASDAQ · Health Care
$128.94as of 10/16/2026
Price chart
Active signals
PTGX Signal Track Record
How signals performed across all stocks →What PTGX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | -0.5% | 47% | September 18, 2026 |
| Bollinger Band Breakout | 30 | +1.1% | 60% | August 6, 2026 |
| Bollinger Band BreakdownActive now | 13 | +4.4% | 77% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +11.0% | 75% | May 7, 2025 |
| Any 20-session window (baseline) | +5.3% | 64% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PTGX
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development f…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 141
- Website
- www.protagonist-inc.com/
Fundamentals
- 1-day range
- $130.61$136.56
- Market cap
- $9.40B
- P/E (trailing)
- 107.21
- P/E (forward)
- -860.82
- EPS (trailing)
- $1.04
- Dividend yield
- —
- Beta
- 1.19
- Avg. volume
- 630.5K
How Protagonist Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2018 annual results
Source: 10-K filed Mar 12, 2019 · via SEC EDGAR / Finnhub
Forecasts
14 analyst ratings
Protagonist Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PTGXProtagonist Therapeutics Inc. Common Stock$128.75▼ 5.71%Market cap $9.40BP/E 107.21$73.08$160.81
- SYRESpyre Therapeutics Inc. Common Stock$79.9▼ 0.25%Market cap $9.12BP/E —$21.01$110.18
- IONSIonis Pharmaceuticals Inc. Common Stock$42.94▼ 2.67%Market cap $9.06BP/E —$42.08$86.74
- RDYDr. Reddy's Laboratories Ltd Common Stock$13.07▲ 1.32%Market cap $10.11BP/E 31.61$1,101$1,415
- CYTKCytokinetics Incorporated Common Stock$61.95▼ 3.08%Market cap $10.13BP/E —$54.3$88.31
- PRAXPraxis Precision Medicines Inc. Common Stock$241.76▼ 2.61%Market cap $10.32BP/E —$50.56$392.7
- ALKSAlkermes plc Ordinary Shares$41.22▲ 2.79%Market cap $8.11BP/E 99.15$27$55.67
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics Inc. Common Stock | $9.40B | 107.21 | $128.75 | ▼ 5.71% | $73.08$160.81 |
| SYRE Spyre Therapeutics Inc. Common Stock | $9.12B | — | $79.9 | ▼ 0.25% | $21.01$110.18 |
| IONS Ionis Pharmaceuticals Inc. Common Stock | $9.06B | — | $42.94 | ▼ 2.67% | $42.08$86.74 |
| RDY Dr. Reddy's Laboratories Ltd Common Stock | $10.11B | 31.61 | $13.07 | ▲ 1.32% | $1,101$1,415 |
| CYTK Cytokinetics Incorporated Common Stock | $10.13B | — | $61.95 | ▼ 3.08% | $54.3$88.31 |
| PRAX Praxis Precision Medicines Inc. Common Stock | $10.32B | — | $241.76 | ▼ 2.61% | $50.56$392.7 |
| ALKS Alkermes plc Ordinary Shares | $8.11B | 99.15 | $41.22 | ▲ 2.79% | $27$55.67 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth With a High-Quality Technical SetupChartMill · 9/23/2026
- Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsightYahoo · 9/21/2026
- J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?Yahoo · 9/18/2026
- Protagonist Therapeutics (NASDAQ:PTGX) Combines High Growth Momentum With a Breakout SetupChartMill · 9/15/2026
- Takeda Secures FDA Approval For First-In-Class Blood Cancer Drugbenzinga · 8/31/2026
Insider Activity
Insider Actions →- Dinesh V. Ph D. Patel · September 10, 2026 · Option Exercise7.3K @ $21.58
- Dinesh V. Ph D. Patel · September 10, 2026 · Sale7.3K @ $144.1
- Dinesh V. Ph D. Patel · September 9, 2026 · Option Exercise63.5K @ $21.58
- Dinesh V. Ph D. Patel · September 9, 2026 · Sale63.5K @ $146.18
- Dinesh V. Ph D. Patel · September 8, 2026 · Option Exercise54.2K @ $21.58
- Dinesh V. Ph D. Patel · September 8, 2026 · Sale54.2K @ $145.87
- Dinesh V. Ph D. Patel · September 3, 2026 · Gift510
- Dinesh V. Ph D. Patel · August 11, 2026 · Option Exercise34.2K @ $21.58
- Dinesh V. Ph D. Patel · August 11, 2026 · Sale34.2K @ $148.52
- Dinesh V. Ph D. Patel · August 10, 2026 · Option Exercise65.8K @ $21.58
- Dinesh V. Ph D. Patel · August 10, 2026 · Sale65.8K @ $149.11
- William D. Waddill · June 23, 2026 · Option Exercise9.0K @ $16.54
- William D. Waddill · June 23, 2026 · Sale9.0K @ $117.94
- William D. Waddill · June 10, 2026 · Option Exercise6.0K @ $16.54
- William D. Waddill · June 10, 2026 · Option Exercise3.0K @ $11.8
Institutional Ownership
March 31, 2026
- Total shares held
- 76.12M
- Total value held
- $7.77B
- Institutional holders
- 319
- Unknown9.78M
- Unknown6.35M
- Unknown5.18M
- Unknown5.06M
- Unknown3.60M
- Unknown3.48M
- Unknown3.12M
- Unknown2.89M
- Unknown2.45M
- Unknown2.16M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
PTGX featured in recent SeekingAlpha and Benzinga articles
A SeekingAlpha column noted Johnson & Johnson’s strong catalysts while keeping a hold stance, a view that may influence sentiment toward biotech peers such as Protagonist Therapeutics. Separately, Benzinga published a piece examining how a $100 investment in PTGX ten years ago would have grown, highlighting the stock’s historical performance. These mentions reflect ongoing analyst and investor interest in the company.
PTGX featured in recent SeekingAlpha and Benzinga articles. A SeekingAlpha column noted Johnson & Johnson’s strong catalysts while keeping a hold stance, a view that may influence sentiment toward biotech peers such as Protagonist Therapeutics. Separately, Benzinga published a piece examining how a $100 investment in PTGX ten years ago would have grown, highlighting the stock’s historical performance. These mentions reflect ongoing analyst and investor interest in the company.